Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Catalent, Inc.    CTLT

CATALENT, INC.

(CTLT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
115.5(c) 119.83(c) 119.67(c) 118.28(c) 116.82(c) Last
808 423 1 025 705 861 233 709 626 914 363 Volume
+0.23% +3.75% -0.13% -1.16% -1.23% Change
More quotes
Financials (USD)
Sales 2021 3 730 M - -
Net income 2021 372 M - -
Net Debt 2021 1 874 M - -
P/E ratio 2021 57,0x
Yield 2021 -
Sales 2022 4 070 M - -
Net income 2022 416 M - -
Net Debt 2022 1 716 M - -
P/E ratio 2022 51,1x
Yield 2022 -
Capitalization 19 240 M 19 240 M -
EV / Sales 2021 5,66x
EV / Sales 2022 5,15x
Nbr of Employees 13 900
Free-Float 99,4%
More Financials
Company
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions... 
Sector
Pharmaceuticals
Calendar
02/02Earnings Release
More about the company
Notations Surperformance© of Catalent, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CATALENT, INC.
01/20CATALENT, INC. : Announces Second Quarter Fiscal Year 2021 Earnings Conference W..
BU
01/20BONE THERAPEUTICS : provides fourth quarter 2020 business update and 2021 outloo..
AQ
01/13ACORDA THERAPEUTICS : Wedbush Backs Acorda Therapeutics' Chelsea Facility Sale, ..
MT
01/13Acorda Therapeutics to Sell Inbrija Manufacturing Operations in Massachusetts..
MT
01/13CATALENT : Agrees to Acquire Dry Powder Inhaler Spray Drying, Capsule Manufactur..
PU
01/11INSIDER TRENDS : Insider Prolongs Selling Trend at Catalent
MT
01/08Stocks Close at Fresh Highs as Biden Promises 'Trillions of Dollars' in Stimu..
MT
01/08Covid-19 Surge Ends Seven Months of U.S. Jobs Growth -- 3rd Update
DJ
01/08U.S. Labor Nonfarm Payrolls Down 140K in December -- 2nd Update
DJ
01/08U.S. Jobs Report to Show Extent of Winter Slowdown
DJ
01/06CATALENT, INC. : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
01/04Covid-19 Vaccines Are in High Demand, but Thousands More Workers Are Needed t..
DJ
2020U.S. Starts Delivery of Moderna's Covid-19 Vaccine
DJ
2020U.S. asked to prioritize frontline essential workers as distribution of Moder..
RE
2020Moderna's COVID-19 vaccine shots leave warehouses, widening U.S. push to immu..
RE
More news
News in other languages on CATALENT, INC.
2020Feu vert aux Etats-Unis pour un deuxième vaccin anti-Covid, celui de Moderna
2020USA : la FDA en passe d'autoriser le vaccin de Moderna
2020CORONAVIRUS : au tour du vaccin de Moderna d'être passé au crible aux USA
2020Moderna, la petite société qui veut résoudre la pandémie
2020CATALENT, INC. : Veröffentlichung des Quartalsergebnisses
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Stock Trading Strategies
CATALENT, INC. - 2020
The trend should continue
BUY
More Stock Trading Analysis
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 117,64 $
Last Close Price 116,82 $
Spread / Highest target 11,3%
Spread / Average Target 0,70%
Spread / Lowest Target -14,4%
EPS Revisions
Managers and Directors
NameTitle
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli President & Chief Operating Officer
Wetteny Joseph Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT, INC.12.25%19 240
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159